Status:
COMPLETED
Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)
Lead Sponsor:
Charite University, Berlin, Germany
Collaborating Sponsors:
German Heart Institute
Conditions:
Renal Cell Cancer Metastatic
Hypertension
Eligibility:
MALE
18-70 years
Brief Summary
Here, it is investigated how sunitinib, a tyrosine kinase-inhibitor targeting vascular endothelial growth factor receptors, might influence sodium homeostasis in the skin and if this is related to a w...
Detailed Description
Tyrosine kinases-inhibitors targeting vascular endothelial growth factor (VEGF)-receptors (RTKIs) are increasingly used in oncology in several metastatic tumor types. These agents are featured by toxi...
Eligibility Criteria
Inclusion
- Age men \> 18 years
- Life-expectation \> 3 months
- Stable weight
- Blood pressure below 140/90 mmHg at baseline
- Estimated glomerular filtration rate \> 45 ml/min/1.73m2
- Willingness to give written informed consent
Exclusion
- Heart failure
- Liver disease with ascites
- Nephrotic syndrome
- Gastrointestinal complaints, preventing normal daily food intake or diarrhea
- Any form of diabetes mellitus
- Known autoimmune diseases
- Acute or chronic infection
- Alcohol or substance abuse
Key Trial Info
Start Date :
November 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2020
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04368546
Start Date
November 1 2015
End Date
March 1 2020
Last Update
January 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Experimental and Clinical Research Center, Clinical Research Unit
Berlin, Germany, 13125